Open AccessResponse to pegylated interferon in a COVID‐19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus
Author(s) -
Frankel Arthur E.,
Yip Wai C.,
Naik Eknath,
Hasselbalch Hans C.
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4218
Subject(s) - everolimus , medicine , clearance , interferon , covid-19 , pegylated interferon , virology , neuroendocrine tumors , alpha interferon , gastroenterology , virus , ribavirin , chronic hepatitis , urology , disease , infectious disease (medical specialty)
Abstract A 61‐year‐old male on everolimus had chronic SARS‐CoV‐2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for COVID‐19.